TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
1. A method of treating an HHLA2-bearing tumor in a subject comprising administering to the subject an amount of a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor, wherein:
the fusion protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:2 or in SEQ ID NO:3.
2. The method of claim 1 wherein the fusion protein comprising an IgV-like domain of a TMIGD2 comprises an Fc portion of an immunoglobulin G.
3. The method of claim 1 wherein the C-terminal residue of the IgV-like domain of a TMIGD2 of the fusion protein is fused via a peptide bond to an N-terminal residue of an Fc portion of an immunoglobulin G.
4. The method of claim 2 , wherein the immunoglobulin G has the sequence of a human immunoglobulin G.
5. The method of claim 2 , wherein the immunoglobulin G is an immunoglobulin G1.
6. The method of claim 1 , wherein the IgV-like domain of the TMIGD2 is conjugated to a cytotoxic agent, and/or wherein the fusion protein is administered in combination with radiation therapy.
7. The method of claim 1 , wherein the IgV-like domain of the TMIGD2 comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:5.
8. The method of claim 1 , wherein administration of the fusion protein inhibits immunosuppression by the HHLA2-bearing tumor.
9. The method of claim 1 , wherein the HHLA2 of the HHLA2-bearing tumor is a human HHLA2.
10. The method of claim 1 , wherein the HHLA2-bearing tumor is a tumor of a breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, or esophagus, or is a hematological tumor.
11. The method of claim 10 , wherein the HHLA2-bearing tumor is a hematological tumor and is a leukemia or a lymphoma.
12. The method of claim 10 , wherein the HHLA2-bearing tumor is a tumor of the breast and is a triple negative breast cancer.
13. The method of claim 1 , wherein the fusion protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:2.
14. The method of claim 1 , wherein the fusion protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:3.